Wall Street brokerages forecast that ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) will post earnings per share of ($0.54) for the current quarter, Zacks reports. Zero analysts have issued estimates for ESSA Pharma’s earnings. ESSA Pharma posted earnings of ($0.39) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 38.5%. The firm is expected to report its next quarterly earnings report on Thursday, December 12th.
According to Zacks, analysts expect that ESSA Pharma will report full year earnings of ($1.33) per share for the current fiscal year, with EPS estimates ranging from ($1.54) to ($1.11). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.22) per share, with EPS estimates ranging from ($1.49) to ($0.94). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover ESSA Pharma.
Several equities research analysts recently issued reports on EPIX shares. Zacks Investment Research upgraded ESSA Pharma from a “sell” rating to a “buy” rating and set a $2.50 price target for the company in a research note on Wednesday, May 22nd. HC Wainwright reiterated a “buy” rating on shares of ESSA Pharma in a research note on Friday, May 17th. Finally, ValuEngine upgraded ESSA Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
About ESSA Pharma
ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Further Reading: Stock Symbols and CUSIP Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.